20.08.2023, 713 Zeichen

Valneva: Valneva, an Austrian/French specialty vaccine company, announced that the U.S. Food and Drug Administration (FDA) has revised the Prescription Drug User Fee Act (PDUFA) action date for the Biologics License Application (BLA) for VLA1553, Valneva’s chikungunya virus vaccine candidate, from the previously communicated end of August to the end of November. The FDA extended the PDUFA date to allow sufficient time to align and agree on the phase 4 program necessary under the accelerated approval pathway. No additional clinical data have been requested for the approval process.
Valneva: weekly performance: -11.29%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (14/08/2023)

Christian Drastil: Wiener Börse Plausch

SportWoche ÖTV-Spitzentennis Podcast: Woche 28 ziemlich erfolglos, aber guter Start in die Generali Open Ladies Kitzbühel jetzt

Bildnachweis

Aktien auf dem Radar:Porr, Kapsch TrafficCom, AT&S, Semperit, RHI Magnesita, Austriacard Holdings AG, OMV, Mayr-Melnhof, Telekom Austria, Lenzing, Strabag, Rosgix, DO&CO, Gurktaler AG VZ, Reploid Group AG, Stadlauer Malzfabrik AG, SW Umwelttechnik, BKS Bank Stamm, Frequentis, Amag, EuroTeleSites AG, CPI Europe AG, Österreichische Post, UBM.

---